OAC
GALT icon

OMERS Administration Corp’s Galectin Therapeutics GALT Stock Holding History

OMERS Administration Corp’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$67.2K Sell
24,100
-39,100
-62% -$119K ﹤0.01% 1049
2025
Q4 		$263K Buy
+63,200
New +$333K ﹤0.01% 844

Other funds holding GALT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

OMERS Administration Corp's GALT Position: Q1 2026 in Review

OMERS Administration Corp reduced its Galectin Therapeutics (GALT) stake by 62% in Q1 2026, selling an estimated $119K and leaving 24,100 shares worth $67.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1049.

OMERS Administration Corp first reported a position in GALT in Q4 2025 and has held it in 2 quarters since. The position peaked at $263K in Q4 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q1 2026.

  • OMERS Administration Corp held 24,100 shares of Galectin Therapeutics worth $67.2K as of Q1 2026.
  • OMERS Administration Corp sold 39,100 Galectin Therapeutics shares in Q1 2026, an estimated $119K.
  • Galectin Therapeutics made up ﹤0.01% of OMERS Administration Corp's portfolio in Q1 2026, its #1049 holding.
  • OMERS Administration Corp first reported a position in Galectin Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • OMERS Administration Corp's Galectin Therapeutics position peaked at $263K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.

Based on OMERS Administration Corp's 13F filing for Q1 2026, filed 15 May 2026.